These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 36727585)

  • 21. Circulating Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Predicts Future Risk of Cardiovascular Events Independently of Established Risk Factors.
    Leander K; Mälarstig A; Van't Hooft FM; Hyde C; Hellénius ML; Troutt JS; Konrad RJ; Öhrvik J; Hamsten A; de Faire U
    Circulation; 2016 Mar; 133(13):1230-9. PubMed ID: 26896437
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mature proprotein convertase subtilisin/kexin type 9, coronary atheroma burden, and vessel remodeling in heterozygous familial hypercholesterolemia.
    Kataoka Y; Harada-Shiba M; Nakao K; Nakashima T; Kawakami S; Fujino M; Kanaya T; Nagai T; Tahara Y; Asaumi Y; Hori M; Ogura M; Goto Y; Noguchi T; Yasuda S
    J Clin Lipidol; 2017; 11(2):413-421.e3. PubMed ID: 28502498
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition with Bococizumab on Lipoprotein Particles in Hypercholesterolemic Subjects.
    Wan H; Gumbiner B; Joh T; Riel T; Udata C; Forgues P; Garzone PD
    Clin Ther; 2017 Nov; 39(11):2243-2259.e5. PubMed ID: 29037448
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of empagliflozin on plasma proprotein convertase subtilisin/kexin type 9 (PCSK9) in patients with type 2 diabetes.
    Tricò D; Raggi F; Distaso M; Ferrannini E; Solini A
    Diabetes Res Clin Pract; 2022 Aug; 190():109983. PubMed ID: 35803317
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Plasma proprotein convertase subtilisin/kexin type 9 concentration and recurrent cardiovascular events in patients with familial hypercholesterolemia.
    Cao YX; Liu HH; Jin JL; Sun D; Guo YL; Wu NQ; Zhu CG; Xu RX; Sun J; Santos RD; Li JJ
    Eur J Prev Cardiol; 2021 Apr; 28(3):272-279. PubMed ID: 33891693
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Proprotein convertase subtilisin/kexin type 9 in patients with systemic sclerosis.
    Ferraz-Amaro I; Delgado-Frías E; Hernández-Hernández V; Sánchez-Pérez H; de Armas-Rillo L; García-Dopico JA; Díaz-González F
    Clin Exp Rheumatol; 2020; 38 Suppl 125(3):18-24. PubMed ID: 32324120
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Circulating proprotein convertase subtilisin-kexin type 9, all-cause mortality, and cardiovascular mortality: The Ludwigshafen Risk and Cardiovascular Health study.
    Silbernagel G; Scharnagl H; Kleber ME; Stojakovic T; März W
    Eur J Prev Cardiol; 2017 Jul; 24(10):1095-1101. PubMed ID: 28436724
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association of circulating proprotein convertase subtilisin/kexin type 9 levels and the risk of incident type 2 diabetes in subjects with prediabetes: a population-based cohort study.
    Shi J; Zhang W; Niu Y; Lin N; Li X; Zhang H; Hu R; Ning G; Fan J; Qin L; Su Q; Yang Z
    Cardiovasc Diabetol; 2020 Dec; 19(1):209. PubMed ID: 33302966
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Plasma proprotein convertase subtilisin/kexin type 9 levels and the risk of first cardiovascular events.
    Ridker PM; Rifai N; Bradwin G; Rose L
    Eur Heart J; 2016 Feb; 37(6):554-60. PubMed ID: 26508163
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association between plasma PCSK9 levels and 10-year progression of carotid atherosclerosis beyond LDL-C: A cohort study.
    Xie W; Liu J; Wang W; Wang M; Qi Y; Zhao F; Sun J; Liu J; Li Y; Zhao D
    Int J Cardiol; 2016 Jul; 215():293-8. PubMed ID: 27128549
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effects of proprotein convertase subtilisin/kexin type 9 inhibitors on lipid metabolism and cardiovascular function.
    Amput P; McSweeney C; Palee S; Phrommintikul A; Chattipakorn SC; Chattipakorn N
    Biomed Pharmacother; 2019 Jan; 109():1171-1180. PubMed ID: 30551367
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Proprotein Convertase Subtilisin/kexin type 9 Inhibition in Cardiovascular Prevention.
    Ali A; Costanzo P; Hoye A
    Curr Pharm Des; 2018; 24(4):442-450. PubMed ID: 29332570
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PCSK9 R46L Loss-of-Function Mutation Reduces Lipoprotein(a), LDL Cholesterol, and Risk of Aortic Valve Stenosis.
    Langsted A; Nordestgaard BG; Benn M; Tybjærg-Hansen A; Kamstrup PR
    J Clin Endocrinol Metab; 2016 Sep; 101(9):3281-7. PubMed ID: 27218270
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interplay between microRNAs, Serum Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9), and Lipid Parameters in Patients with Very High Lipoprotein(a) Treated with PCSK9 Inhibitors.
    Levstek T; Karun T; Rehberger Likozar A; Šebeštjen M; Trebušak Podkrajšek K
    Genes (Basel); 2023 Mar; 14(3):. PubMed ID: 36980904
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Associations of pro-protein convertase subtilisin-like kexin type 9, soluble low-density lipoprotein receptor and coronary artery disease: A case-control study.
    Peng J; Xing CY; Zhao K; Deng J; Olmedo DA; Ma Z; Zhang M; Wang Y
    Int J Cardiol; 2022 Mar; 350():9-15. PubMed ID: 35007650
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Proprotein Convertase Subtilisin/Kexin Type 9 Loss-of-Function Is Detrimental to the Juvenile Host With Septic Shock.
    Atreya MR; Whitacre BE; Cvijanovich NZ; Bigham MT; Thomas NJ; Schwarz AJ; Weiss SL; Fitzgerald JC; Allen GL; Lutfi R; Nowak JE; Quasney MW; Shah AS; Wong HR
    Crit Care Med; 2020 Oct; 48(10):1513-1520. PubMed ID: 32769621
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Proprotein convertase subtilisin/kexin type 9 is associated with atherosclerosis in patients with Behcet's disease.
    Aydogan Baykara R; Yilmaz PD; Göktepe MH; Kadiyoran C; Ogul M; Kucuk A; Cumhur Cüre M; Cüre E
    Clin Exp Hypertens; 2022 Jul; 44(5):480-486. PubMed ID: 35502687
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Relation of Proprotein Convertase Subtilisin/Kexin Type 9 to Cardiovascular Outcomes in Patients Undergoing Percutaneous Coronary Intervention.
    Choi IJ; Lim S; Lee D; Lee WJ; Lee KY; Kim MJ; Jeon DS
    Am J Cardiol; 2020 Oct; 133():54-60. PubMed ID: 32798044
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PCSK9 and Cardiovascular Disease in Individuals with Moderately Decreased Kidney Function.
    Kheirkhah A; Lamina C; Kollerits B; Schachtl-Riess JF; Schultheiss UT; Forer L; Sekula P; Kotsis F; Eckardt KU; Kronenberg F;
    Clin J Am Soc Nephrol; 2022 Jun; 17(6):809-818. PubMed ID: 35387881
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Stabilization of vulnerable carotid plaques with proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab.
    Ogata A; Oho K; Matsumoto N; Masuoka J; Inoue K; Koguchi M; Yoshioka F; Abe T
    Acta Neurochir (Wien); 2019 Mar; 161(3):597-600. PubMed ID: 30729307
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.